ArticleBlood2022
Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Standardization of In-Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2026Guideline
- Article
- The Gut-Iron-Immune Axis in Severe Anaemia and Bacteraemia.Nutrients · 2026Review
- Baseline Hypohaptoglobinemia as a Predisposing Factor for Hemolysis-Related Acute Kidney Injury After Pulsed-Field Ablation.JACC. Case reports · 2026Article
- Antibody-Dependent and Antibody-Independent Hemolysis in Sickle Cell Disease.Antibodies (Basel, Switzerland) · 2026Review
- Article
- From Exposure to Outcome: Air Pollution-Induced Oxidative Stress as a Determinant of Early and Late Outcomes After Coronary Artery Bypass Grafting.Antioxidants (Basel, Switzerland) · 2026Review
- Article
- Standardization ofPerfusion · 2026Review
- Review
- Iron Compartmentalisation and Vascular Endothelial Cell Dysfunction.Antioxidants (Basel, Switzerland) · 2026Review
- Cryo-EM provides insight into how thebioRxiv : the preprint server for biology · 2026Article
- Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypes.EBioMedicine · 2026Review
- Impact of heme on the therapeutic efficacy of anti-CD20 antibodies.The Journal of biological chemistry · 2026Article
- Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Standardization of In Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development.Artificial organs · 2026Review
- Review
- A Zeolitic Pyrimidine Framework (ZPF) Nanoplatform Co-Delivers a DNAzyme and a Protein Prodrug for Cascade-Activated Tumour Therapy.Cell proliferation · 2026Article
- Radiation Countermeasure Gamma-Tocotrienol Inhibits Accumulation of Lipid Peroxidation Products in the Serum of Nonhuman Primates Exposed to Partial- or Total-Body Radiation-A Hallmark of Inhibition of Irradiation-Induced Ferroptosis?International journal of molecular sciences · 2026Article
- Standardization of In-Vitro Evaluation of Extracorporeal Life Support (ECLS) Devices for Research and Development.Interdisciplinary cardiovascular and thoracic surgery · 2026Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
During hemolysis, erythrophagocytes dispose damaged red blood cells. This prevents the extracellular release of hemoglobin, detoxifies heme, and recycles iron in a linked metabolic pathway. Complementary to this process, haptoglobin and hemopexin scavenge and shuttle the red blood cell toxins hemoglobin and heme to cellular clearance. Pathological hemolysis outpaces macrophage capacity and scavenger synthesis across a diversity of diseases. This imbalance leads to hemoglobin-driven disease progression. To meet a void in treatment options, scavenger protein-based therapeutics are in clinical development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.